Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COMMAND
- Sponsors AbbVie
- 19 Feb 2024 According to AbbVie Media Release, data from the study will be presented at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
- 11 Oct 2023 Planned End Date changed from 22 May 2024 to 25 Sep 2028.
- 11 Oct 2023 Planned primary completion date changed from 22 May 2024 to 25 Sep 2028.